Aytu BioPharma, Inc. (AYTU)

Market Cap	9.16M
Revenue (ttm)	79.76M
Net Income (ttm)	-6.25M
Shares Out	6.15M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	2.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,980
Open	1.582
Previous Close	1.565
Day's Range	1.460 - 1.582
52-Week Range	1.410 - 3.450
Beta	-1.40
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About AYTU

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to trea...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Joshua Disbrow
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: AYTU
• Website: https://aytubio.com

Financial Performance

In 2024, Aytu BioPharma's revenue was $81.00 million, a decrease of -24.58% compared to the previous year's $107.40 million. Losses were -$15.84 million, -7.08% less than in 2023.